Periodic Reporting for period 1 - CryoBiopsy (CryoBiopsy: a bi-modal temperature sample preservation device for standardized breast cancer biopsy)
Reporting period: 2017-02-01 to 2017-05-31
Current advances in biomedicine make an increased use of sophisticate molecular technologies which, rather than looking only at tissue morphology, analyse changes in biomolecules involved in cellular pathways that are altered during cancer progression (biomarkers). The technologies behind the analysis of biomarkers require tissue that has not been compromised by traditional biopsy fixation methodology with formalin. Biomarkers are extremely sensitive to degradation, and tissue must be frozen as soon as possible. Unfortunately, current biopsy devices are not designed to meet this challenge.
We have developed two different devices to automatically split the tissue sample in two during biopsy acquisition. These devices enable formalin fixation, which is ideal for histology analysis, and freezing of the other part for biomarker analysis.
For our company, CryoBiopsy will generate cumulative revenues of €39.5 million after five years of commercialization and the creation of 20 positions